Evidence map›Paper›PMID 38961436›Full record

ArticleJournal of translational medicine2024

Carbohydrate antigen 125 on epicardial fat and its association with local inflammation and fibrosis-related markers.

Sonia Eiras, Rafael de la Espriella, Xiaoran Fu, Diego Iglesias-Álvarez, Rumeysa Basdas, J R Núñez-Caamaño, J M Martínez-Cereijo, L Reija, A L Fernández, David Sánchez-López and 3 more

Abstract read
In one paragraph

Article in Journal of translational medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Sonia Eiras *Translational Cardiology Group, Health Research Institute, Santiago de Compostela, Spain.ORCID 0000-0001-7200-253X
Rafael de la Espriella *Centro de Investigación Biomédica en Red en Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain.
Xiaoran FuTranslational Cardiology Group, Health Research Institute, Santiago de Compostela, Spain.
Diego Iglesias-ÁlvarezCoronary Unit. Cardiovascular Department, University Hospital of Santiago de Compostela, Santiago de Compostela, Spain.
Rumeysa BasdasTranslational Cardiology Group, Health Research Institute, Santiago de Compostela, Spain.
J R Núñez-CaamañoTranslational Cardiology Group, Health Research Institute, Santiago de Compostela, Spain.
J M Martínez-CereijoHeart Surgery Department, University Hospital of Santiago de Compostela, Santiago de Compostela, Spain.
L ReijaHeart Surgery Department, University Hospital of Santiago de Compostela, Santiago de Compostela, Spain.
A L FernándezHeart Surgery Department, University Hospital of Santiago de Compostela, Santiago de Compostela, Spain.
David Sánchez-LópezTranslational Cardiology Group, Health Research Institute, Santiago de Compostela, Spain.
Gema MiñanaDepartment of Cardiology, Hospital Clínico Universitario de Valencia (INCLIVA), Avda. Blasco Ibáñez 17, 46010, Valencia, Spain.
Julio NúñezCentro de Investigación Biomédica en Red en Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain. yulnunez@gmail.com.
José R González-JuanateyCentro de Investigación Biomédica en Red en Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain. jose.ramon.gonzalez.juanatey@sergas.es.

Funding

CIBERCV CB16/11/0026CIBERCV CB16/11/00420Consellería de Economía, Emprego e Industria, Xunta de Galicia IN607B-2022-04ISCIII PI19/01330
6 · The paper itself

Abstract

backgroundCarbohydrate antigen 125 (CA125) is a proteolytic fragment of MUC-16 that is increased in heart failure (HF) and associated with inflammation, fluid overload, and worse adverse events. Our main objective was to study the expression of CA125 on epicardium and its association with inflammation, adipogenesis, and fibrosis.

methodsEpicardial fat biopsies and blood were obtained from 151 non-selected patients undergoing open heart surgery. Immunohistochemistry, ELISA, or real-time PCR were used for analyzing protein or mRNA expression levels of CA125 and markers of inflammatory cells, fibroblasts, and adipocytes. Epithelial or stromal cells from epicardium were isolated and cultured to identify CA125 and its association with the adipogenesis and fibrosis pathways, respectively.

resultsThe median age was 71 (63-74) years, 106 patients (70%) were male, and 62 (41%) had an established diagnosis of HF before surgery. The slice of epicardial fat biopsy determined a positive and colorimetric staining on the epithelial layer after incubating with the CA125 M11 antibody, providing the first description of CA125 expression in the human epicardium. Epicardial CA125 showed a strong and positive correlation with markers of inflammation and fibrosis in the epicardial fat tissue while exhibiting a negative correlation with markers of the adipogenesis pathway. This relationship remained significant after adjusting for potential confounders such as a prior HF diagnosis and plasma CA125 levels.

conclusionEpicardial cells express CA125, which is positively associated with inflammatory and fibroblast markers in epicardial adipose tissue. These results suggest that CA125 may be biologically involved in HF progression (transition from adipogenesis to fibrosis).

Indexed as

Adipose TissueBiomarkersCA-125 AntigenFibrosisInflammationPericardiumAdipogenesisAgedEpicardial Adipose TissueFemaleHumansMaleMiddle AgedBiomarkersCA-125 AntigenCA125EpicardiumHeart failureMUC16

Identifiers

PMID38961436
PMCPMC11223376

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.